<!DOCTYPE html>
<html lang="en">
<head><!-- Google Tag Manager --> <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-N4XZHNC');</script> <!-- End Google Tag Manager -->

<title>Prostate Cancer: Diagnosis and Staging</title>
  <meta charset="utf-8">
  
  <link href="urology.css" rel="stylesheet">

<meta name="keywords" content="prostate cancer, staging" >
<meta name="description" content="Prostate cancer diagnosis: staging, from the online textbook of urology by D. Manski" >
<meta name="author" content="Dr. med. Dirk Manski" >
<meta name="copyright" content="Dirk Manski" >
<meta name="robots" content="index">
<meta name="robots" content="follow">
<meta name="viewport" content="width=device-width, initial-scale=1">
 </head>

<body><!-- Google Tag Manager (noscript) --> <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-N4XZHNC" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <!-- End Google Tag Manager (noscript) --> 
<header>
    <a class="ribbon" tabindex="-1" title="back to start!" href="https://www.urology-textbook.com/index.html">
	   <h5 id="logo">urology-textbook.com</h5>
       <p>Dr. med. Dirk Manski</p>
    </a>  
</header>
<main>
<nav id="navigation">
<ul>
<li><a href="https://www.urology-textbook.com/index.html">Start</a></li>
<li><a href="https://www.urology-textbook.com/anatomy.html">Anatomy</a></li>
<li><a href="https://www.urology-textbook.com/signs-and-symptoms.html">Signs and Symptoms</a></li>
<li><a href="https://www.urology-textbook.com/examinations.html">Examinations</a></li>
<li><a href="https://www.urology-textbook.com/surgical-management.html">Surgical Management</a></li>
<li><a href="https://www.urology-textbook.com/pharmacology.html">Pharmacology</a></li>
<li><a href="https://www.urology-textbook.com/kidneys.html">Kidneys</a></li>
<li><a href="https://www.urology-textbook.com/ureters.html">Ureters</a></li>
<li><a href="https://www.urology-textbook.com/bladder.html">Bladder</a></li>
<li><a href="https://www.urology-textbook.com/prostate.html">Prostate</a></li>
<li><a href="https://www.urology-textbook.com/urethra.html">Urethra</a></li>
<li><a href="https://www.urology-textbook.com/penis.html">Penis</a></li>
<li><a href="https://www.urology-textbook.com/testes.html">Testes</a></li>
<li><a href="https://www.urology-textbook.com/adrenal-glands.html">Adrenal Glands</a></li>
<li><a href="https://www.urology-textbook.com/common-diseases.html">Common Diseases</a></li>
<li><a href="https://www.urology-textbook.com/urologic-surgery.html">Urologic Surgery</a></li>
<li><a href="https://www.urology-textbook.com/index-urology.html">Index</a></li>
<li><a href="https://www.urology-textbook.com/medical-abbreviations.html">Abbreviations</a></li>
<li><a href="https://www.urology-textbook.com/urology-news.html">News</a></li>
<li><a href="https://www.urology-textbook.com/links.html">Links</a></li>
</ul>
 
</nav>
<article>

<p id="brotkrumen">&nbsp;You are here: <a href="https://www.urology-textbook.com/index.html">Urology Textbook</a> &gt; <a href="https://www.urology-textbook.com/prostate.html">Prostate</a> &gt; <a href="https://www.urology-textbook.com/prostate-cancer.html">Prostate cancer</a> &gt; Staging</p>
<h1>Prostate Cancer: Diagnosis and Staging</h1>

<ul title="prostate cancer sections">
<li><a href="https://www.urology-textbook.com/prostate-cancer.html">Prostate cancer: Epidemiology and etiology </a> </li>

<li><a href="https://www.urology-textbook.com/prostate-cancer-pathology.html">Prostate cancer: Pathology</a> </li>
<li><a href="https://www.urology-textbook.com/prostate-cancer-signs-and-symptoms.html">Prostate cancer: Signs and symptoms</a> </li>
<li><a href="https://www.urology-textbook.com/prostate-cancer-screening.html">Prostate cancer: Screening</a> </li>
<li><strong>Prostate cancer: Staging</strong> </li>
<li><a href="https://www.urology-textbook.com/prostate-cancer-treatment-options.html">Prostate cancer: Treatment options</a></li>
<li><a href="https://www.urology-textbook.com/prostate-cancer-active-surveillance.html">Prostate cancer: Active surveillance</a></li>
<li><a href="https://www.urology-textbook.com/prostate-cancer-prostatectomy.html">Prostate cancer: Prostatectomy</a></li>
<li><a href="https://www.urology-textbook.com/prostate-cancer-radiation-therapy.html">Prostate cancer: Radiation therapy</a> </li>
<li><a href="https://www.urology-textbook.com/prostate-cancer-brachytherapy.html">Prostate cancer: Brachytherapy</a></li>
<li><a href="https://www.urology-textbook.com/prostate-cancer-turp-hifu.html">Prostate cancer: TURP and experimental treatment options </a></li>
<li><a href="https://www.urology-textbook.com/prostate-cancer-hormonal-therapy.html">Prostate cancer: Hormonal therapy of advanced prostate cancer</a></li>
<li><a href="https://www.urology-textbook.com/prostate-cancer-castration-resistant.html">Prostate cancer: Treatment of castration-resistant prostate cancer</a></li>
</ul>
<br>

<p>Guidelines and review literature: (<a href="https://uroweb.org/guidelines/prostate-cancer/">EAU Guidelines Prostate Cancer</a>) (<a href="https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/">S3-Leitlinie Prostatakarzinom</a>) (Walsh-Campbell Urology).</p>
<p>
Of crucial importance for any therapeutic decision is both the assessment of the tumor stage and the evaluation of the biological aggressiveness of the prostate cancer. Staging includes digital-rectal examination (DRE), PSA concentration, results of the prostate needle biopsy, laboratory tests, imaging, and pelvic lymphadenectomy.
</p>

<h3>Clinical Staging of Prostate Cancer </h3> 
<p>Clinical staging is done with digital-rectal examination, PSA concentration, and Gleason score of the prostate biopsy. Each parameter has a statistical correlation with the pathologic tumor stage. The prediction accuracy of a single parameter is too low in individual patients. The prediction of the clinical risk (prostate cancer mortality) is accurate with the combined consideration [see table <a href="#pca_risiko_damico">risk stratification of prostate cancer</a>].  </p>

<small>
<table border="1" width="90%">
<caption><strong><a NAME="pca_risiko_damico">D’Amico risk classification for prostate cancer:</a></strong> clinical risk (mortality) for localized prostate cancer before definitive treatment (D'Amico et al., 2003).  (*) Figures represent cancer-specific mortality. EBRT: external beam radiotherapy. RPE: radical prostatectomy</caption>
<thead>
<tr>
<td>Risk</td>
<td>Criteria</td>
<td>10-year mortality after EBRT (*)</td>
<td>10-year risk of PSA Prgression after RPE</td>
<td>10-year mortality after RPE (*)</td>
</tr>
</thead>
<tbody>
<tr>
<td>Low</td>
<td>PSA &lt;10 ng/ml <i>and</i> Gleason score&nbsp;&leq;6</td>
<td>2%</td>
<td>17%</td>
<td>1%</td>
</tr>
<tr>
<td>Intermediate</td>
<td>PSA 10&ndash;20 ng/ml <i>or</i> Gleason score 7</td>
<td>8%</td>
<td>54%</td>
<td>4%</td>
</tr>
<tr>
<td>High</td>
<td>PSA &gt;20 ng/ml <i>or</i> Gleason score&nbsp;&gt;7</td>
<td>24%</td>
<td>71%</td>
<td>11%</td>
</tr>
</tbody>
</table> 
</small>

<p>Another important risk factor is PSA velocity in the year before treatment; unfavorable is a rise of more than 2 ng/ml (D'Amico et al., 2006). With additional consideration of the tumor burden in the prostate biopsy, the prediction accuracy will be even better. With additional consideration of the tumor burden in the prostate biopsy, the prediction accuracy will be even better (CAPRA score), see table <a href="#pca_capra_score">CAPRA-Score</a>. CAPRA stands for Cancer of the Prostate Risk Assessment and was developed by the University of California, San Francisco based on data from the CaPSURE study (Cooperberg et al., 2009). See table  <a href="#pca_capra_prognose">pathologic outcomes and prognosis after radical prostatectomy</a> as a function of the CAPRA score. </p>


<table border="1" width="90%">
    <caption><strong><a NAME="pca_capra_score">CAPRA-Score for clinical risk stratification of prostate cancer</a></strong>, based on the data of the CaPSURE trial \parencite{Cooperberg2009}. See also table <a href="#pca_capra_prognose">pathologic outcomes and prognosis after radical prostatectomy</a> as a function of the CAPRA score.
<br>
0&ndash;2 points: low risk.<br>
3&ndash;5 points: intermediate risk.<br>
6&ndash;10 points: high risk.</caption>
<thead>
<tr>
<td>Risk factor</td>
<td>Criteria</td>
<td>Points</td>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>&lt; 50 years</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>&gt; 50 years</td>
<td>1</td>
</tr>
<tr>
<td>PSA</td>
<td>&lt; 6 ng/ml</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>6,1&ndash;10 ng/ml</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>10,1&ndash;20 ng/ml</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>20,1&ndash;30 ng/ml</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>&gt; 30 ng/ml</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>&gt; 30 ng/ml</td>
<td>4</td>
</tr>
<tr>
<td>Biopsy Gleason score</td>
<td>No pattern 4 or 5</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Secondary pattern 4 oder 5</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Primary pattern 4 oder 5</td>
<td>3</td>
</tr>
<tr>
<td>Clinical stage</td>
<td>T1&ndash;2</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>&ge; T3a</td>
<td>1</td>
</tr>
<tr>
<td>Positive cores in biopsy</td>
<td>&lt; 34%</td>
<td>0</td>
</tr>  
<tr>
<td></td>
<td>&gt; 34%</td>
<td>1</td>
</tr> 
</tbody>
</table> 
<br>
<br>

<small>
<table border="1" width="90%">
    <caption><strong><a NAME="pca_capra_score">Pathologic outcomes and prognosis (figures in percent) after radical prostatectomy</a></strong> depending on the CAPRA score (Cooperberg u.a., 2009) (Budaeus u.a., 2012). The data from the cited studies were rounded and expressed as an interval. See table <a href="#pca_capra_score">CAPRA-Score</a> for the determination of the CAPRA score. </caption>
<thead>
<tr>
<td>CAPRA score </td>
<td> 0&ndash;1 </td>
<td> 2 </td>
<td> 3 </td>
<td> 4 </td>
<td> 5 </td>
<td> 6 </td>
<td> &gt;7</td>
</tr>         
</thead>
<tbody>
<tr>
<td>Positive surgical margin</td>
<td> 8&ndash;24 </td>
<td> 15&ndash;26 </td>
<td> 16&ndash;31 </td>
<td> 18&ndash;42 </td>
<td> 26&ndash;44 </td>
<td> 44&ndash;53 </td>
<td> 42&ndash;58 </td>
</tr>
<tr>
<td>Extracapsular extension</td>
<td> 6&ndash;14 </td>
<td> 16&ndash;19 </td>
<td> 23&ndash;26 </td>
<td> 26&ndash;40 </td>
<td> 44&ndash;55 </td>
<td> 51&ndash;56 </td>
<td> 68&ndash;86 </td>
</tr>
<tr>
<td>Seminal vesicle infiltration</td>
<td> 1&ndash;2 </td>
<td> 3&ndash;4 </td>
<td> 4&ndash;6 </td>
<td> 9&ndash;11 </td>
<td> 13&ndash;21 </td>
<td> 22 </td>
<td> 27&ndash;47 </td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td> 0&ndash;1 </td>
<td> 1&ndash;3 </td>
<td> 2 </td>
<td> 1&ndash;4 </td>
<td> 3&ndash;11 </td>
<td> 4&ndash;11 </td>
<td> 3&ndash;34 </td>
</tr>
<tr>
<td>3 years progression free</td>
<td> 92&ndash;95 </td>
<td> 84&ndash;95 </td>
<td> 76&ndash;87 </td>
<td> 73&ndash;82 </td>
<td> 67&ndash;70 </td>
<td> 46&ndash;72 </td>
<td> 35&ndash;50 </td>
</tr>
<tr>
<td>5 years progression free</td>
<td> 86&ndash;91 </td>
<td> 75&ndash;91 </td>
<td> 65&ndash;83 </td>
<td> 60&ndash;74 </td>
<td> 52&ndash;61 </td>
<td> 29&ndash;62 </td>
<td> 20&ndash;30 </td>
</tr>
</tbody>
</table>
</small>

<p>The <I>Partin tables</I> combine local tumor stage, PSA level, and Gleason score to <a href="https://www.hopkinsmedicine.org/brady-urology-institute/conditions-and-treatments/prostate-cancer/risk-assessment-tools/partin-tables">predict pathology results after radical prostatectomy</a>. The tables are based on the pathological results at the James Buchanan Brady Urological Institute. Some authors think that the Partin tables underestimate the risk of lymph node metastasis. The reason may be the limited dissection field used in this clinical series. </p>

<p>The <a href=“https://www.mskcc.org/nomograms/prostate”>Kattan nomograms of the Memorial Sloan Kettering Cancer Center</a> also use the combination of local tumor stage, PSA concentration and Gleason sum. As a result of the nomogram, the investigator receives the 10-year progression-free survival rate after radical prostatectomy and the 15-year cancer-specific survival rate. </p>

<h3>Bone Scintigraphy</h3>
<p>Bone scan is used to diagnose bone metastases of prostate cancer. It has a relatively high sensitivity with poor specificity [figure <a href="#Szinti_Knochenmetastasen">prostate cancer bone metastasis</a>]. Suspect lesions need further diagnostic workup with X-rays, CT, MRI, or bone biopsy. </p>
<p>For PSA concentration below 10 ng/ml, the rate of bone metastases in prostate cancer is very low (1.3%) at a constant rate of false-positive findings. In patients with an organ-confined tumor, PSA less than 10 ng/ml, a Gleason score below, 8 and missing bone pain, <a href="https://www.urology-textbook.com/renal-scintigraphy.html">bone scintigraphy</a> can be safely omitted before curative treatment.
</p>

<a NAME="Szinti_Knochenmetastasen"></a>
<table width=100%>
<tr><td><img src="https://images2.urology-textbook.com/Szinti_Knochenmetastasen.jpg" alt="figure: Bone scintigraphie with multiple metastasis in a patient with prostate cancer and PSA of 100 ng/ml"></td>
</tr>
<caption><strong>Bone scintigraphy in a patient with prostate cancer and PSA of 100 ng/ml. </strong> There are multiple lesions in the spine, sacrum, and ribs. With kind permission, Dr. G. Antes, Kempten.</caption>
</table>

<h3>Computed Tomography</h3>
<p>A <a href="https://www.urology-textbook.com/ct-scan.html">CT scan</a> is able to identify enlarged lymph nodes, hydronephrosis, bone metastases and infiltration of neighboring organs of the primary tumor. In patients with a PSA below 20 ng/ml and a Gleason score below 8, the pathologies mentioned above are rare. The significance of enlarged lymph nodes is limited (not specific and may be false-positive). A CT scan is indicated in patients with high-risk prostate carcinoma, either in combination with bone scintigraphy or PET (see next section).
</p>

<h3>Positron Emission Tomography </h3>
<p>PET (in combination with a CT or MRI) yields high diagnostic accuracy and is superior to the combination of bone scintigraphy and CT (Hofman u.a., 2020). <sup>68</sup>Ga-PSMA is used as a tracer. Indications for PSMA-PET-CT include high-risk prostate cancer, biochemical recurrence after curative therapy, or progression with systemic treatment for metastatic prostate cancer.  </p>
 

<h3>Multiparametric MRI of the Prostate </h3>
<p>MRI of the prostate is indicated for imaging of locally advanced prostate cancer if imaging results would change the treatment decision. </p>


<h3>Pelvic Lymphadenectomy</h3>
<p>Pelvic lymphadenectomy is necessary for the exact diagnosis of nodal metastasis. Any imaging technique can only detect lymph node enlargement and is, therefore, neither sensitive nor specific. Surgical (laparoscopic) nodal staging as an isolated intervention is seldom indicated in patients with a higher risk of lymph node metastasis, particularly before perineal prostatectomy or brachytherapy. See section surgical techniques/pelvic lymphadenectomy for details of the procedure. </p>

<p>The dissection field of pelvic lymphadenectomy is debated (limited versus extended). The boundaries for a limited dissection are:</p>
<ul>
<li>Lateral boundary: external iliac artery</li>
<li>Kaudal boundary: superior ramus of the pubis</li>
<li>Cranial boundary: bifurcation of the common iliac artery</li>
<li>Medial boundary: bladder, branches of the internal iliac artery</li>
<li>Dorsal boundary: obturator fossa</li>
</ul><p>In low-risk tumors (Gleason score &lt;7 and PSA &lt; 10 ng/ml), the probability of lymph node metastasis is very low (&lt; 5%). Pelvic lymphadenectomy is unnecessary before curative treatment. In low-risk patients, the need for surgical lymph node staging, even during retropubic prostatectomy, is controversial and debated. Some authors believe that the incidence of lymph node metastases is underestimated (e.g., in the Partin tables, see above). They demand to perform extended pelvic lymphadenectomy if radical prostatectomy is necessary. </p><p>As an alternative for extended lymphadenectomy in low-risk patients, some centers perform sentinel lymphadenectomy. After injection of a radioactive tracer in the prostate, sentinel lymph nodes are intraoperatively detected with a gamma probe and removed. Sentinel lymphadenectomy limits the dissection field, and sensitivity is higher than in standard lymphadenectomy (Wawroschek et al., 2003). Controlled trials for sentinel lymphadenectomy are not available; the procedure is time-consuming and expensive.  </p>
 

<h2>Experimental Diagnostic Procedures</h2>

<h3>New Tumor Markers for Screening</h3>

<h4>PCA3 (prostate cancer antigen 3)</h4>
<p>PCA3 is a non-protein-coding RNA, which is highly overexpressed in prostate cancer cells and can be detected in the urine after prostate massage (DRE). Initial studies indicate a better sensitivity and specificity for PCA3 in men with elevated PSA. In addition, PCA3 may play a role in future treatment algorithms, since tumor volume can be predicted (Auprich et al., 2011). In Germany, the PCA3 tests cost around 300 euros. </p>

<h4>Analysis of Gene Expression </h4>
<p>Prolaris is a diagnostic test from Myriad Genetics, which analyzes the RNA expression of cell cycle genes in prostate biopsy tissue. Thirty proliferation genes are examined, and 15 housekeeping genes serve as controls (Cuzick et al., 2012). The test claims to increase the safety for patients with low-risk cancer choosing active surveillance, but controlled studies are lacking. The test is costly (around 3000 dollars). </p>

<h4>Other Methods: </h4>
<p>Detection of micrometastases in bone marrow, RT-PCR for detecting prostate cancer cells in the blood or lymph nodes. </p>

<h3>New Techniques for Imaging </h3>
<p> New methods and tracers improve imaging with PET, MRI, or ultrasound.
</p>

<h4>Micro-ultrasound:</h4> 
<p>Targeted prostate biopsy with a high-resolution TRUS probe (ExactVu with 29 MHz) was able to achieve better results than conventional systematic biopsy in several studies (Dariane et al., 2022).</p>

<h4>Elastography: </h4>
<p>The elasticity of the prostate tissue can be displayed in color with the help of a special ultrasonic probe and pressure on the prostate. Less elastic regions are suspicious for cancer. Elastography is better in prostate cancer detection than normal gray-scale imaging. The sensitivity and specificity of elastography is 60&ndash;70%, but this not sufficient to omit prostate biopsy in patients with elevated PSA if imaging appears normal (Brock et al., 2012). In addition, elastography helps target prostate biopsy.  </p>

<h4>Analysis of the Ultrasonography Raw Data: </h4>

<p>HistoScanning is a database-assisted analysis of the raw data from the ultrasound probes and is supposed to be better than conventional gray-scale imaging to detect prostate cancer. HistoScanning is already available for a fee (per application 200&ndash;500 Euros). Independent trials could not confirm initial promising results (Schiffmann et al., 2014) (Javed et al., 2014). </p>

<h4>MRI imaging: </h4> <p>MRI with magnetic nanoparticles or diffusion-weighted imaging (DWI) increases the detection accuracy of lymph node metastases  (Harisinghani et al., 2003).
</p>
<br>
<br>

<div id="ad-footer">
<!-- ad-footer -->
<ins class="adsbygoogle"
     style="display:inline-block;width:500px;height:250px"
     data-ad-client="ca-pub-9284927104423861"
     data-ad-slot="8746163219"></ins>
 <script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>
</div>
<br><table id="navigation_unten">
<tr>
 
<td><a href="https://www.urology-textbook.com/prostate-cancer-screening.html">Prostate cancer screening</a></td>
<td><a class="nav4" href="https://www.urology-textbook.com/index-urology.html">Index</a></td>
<td><a class="nav3" href="https://www.urology-textbook.com/prostate-cancer-treatment-options.html">Prostate cancer treatment options</a></td>
 
</tr>
</table>

<br>
<br>
Index: <a href="https://www.urology-textbook.com/index-urology-a.html">1&ndash;9</a> <a href="https://www.urology-textbook.com/index-urology-a.html">A</a> <a href="https://www.urology-textbook.com/index-urology-b.html">B</a> <a href="https://www.urology-textbook.com/index-urology-c.html">C</a> <a href="https://www.urology-textbook.com/index-urology-d.html">D</a> <a href="https://www.urology-textbook.com/index-urology-e.html">E</a> <a href="https://www.urology-textbook.com/index-urology-f.html">F</a> <a href="https://www.urology-textbook.com/index-urology-g.html">G</a> <a href="https://www.urology-textbook.com/index-urology-h.html">H</a> <a href="https://www.urology-textbook.com/index-urology-i.html">I</a> <a href="https://www.urology-textbook.com/index-urology-j.html">J</a> <a href="https://www.urology-textbook.com/index-urology-k.html">K</a> <a href="https://www.urology-textbook.com/index-urology-l.html">L</a> <a href="https://www.urology-textbook.com/index-urology-m.html">M</a> <a href="https://www.urology-textbook.com/index-urology-n.html">N</a> <a href="https://www.urology-textbook.com/index-urology-o.html">O</a> <a href="https://www.urology-textbook.com/index-urology-p.html">P</a> <a href="https://www.urology-textbook.com/index-urology-q.html">Q</a> <a href="https://www.urology-textbook.com/index-urology-r.html">R</a> <a href="https://www.urology-textbook.com/index-urology-s.html">S</a> <a href="https://www.urology-textbook.com/index-urology-t.html">T</a> <a href="https://www.urology-textbook.com/index-urology-u.html">U</a> <a href="https://www.urology-textbook.com/index-urology-v.html">V</a> <a href="https://www.urology-textbook.com/index-urology-w.html">W</a> <a href="https://www.urology-textbook.com/index-urology-xyz.html">X Y Z</a> 

<br>
<h3>References</h3>



<p>Afshar-Oromieh, A.; Haberkorn, U.; Schlemmer, H. P.; 
        Fenchel, M.; Eder, M.; Eisenhut, M.; Hadaschik, B. A.; Kopp-Schneider, A. 
        &amp; R&#246;thke, M.
        Comparison of PET/CT and PET/MRI hybrid systems 
        using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate 
        cancer: initial experience.<br><em>Eur J Nucl Med Mol Imaging, </em><b>2014</b><i>, 
        41</i>, 887-897
        <br>
        <br>Auprich, M.; Bjartell, A.; Chun, F. K.; de la Taille, 
        A.; Freedland, S. J.; Haese, A.; Schalken, J.; Stenzl, A.; Tombal, B. &amp; 
        van der Poel, H.
        Contemporary role of prostate cancer antigen 3 in the 
        management of prostate cancer.<br><em>Eur Urol, </em><b>2011</b><i>, 60</i>, 
        1045-1054.</p>
    
<p>Brock, M.; von Bodman, C.; Palisaar, R. J.; L&#246;ppenberg, 
        B.; Sommerer, F.; Deix, T.; Noldus, J. &amp; Eggert, T.
        The Impact of 
        Real-Time Elastography Guiding a Systematic Prostate Biopsy to Improve 
        Cancer Detection Rate: A Prospective Study of 353 Patients.<br><em>J Urol, </em><b>2012</b>.</p>
<p>
D'Amico, A. V.; Moul, J.; Carroll, P. R.; Sun, L.; 
    Lubeck, D. &amp; Chen, M.
    Cancer-specific mortality after surgery or 
    radiation for patients with clinically localized prostate cancer managed 
    during the prostate-specific antigen era.<br><em>J Clin Oncol, </em><b>2003</b><i>, 
    21</i>, 2163-2172.
    <br>
    <br>
    D'Amico, A. V.; Hui-Chen, M.; Renshaw, A. A.; Sussman, 
    B.; Roehl, K. A. &amp; Catalona, W. J.
    Identifying men diagnosed with 
    clinically localized prostate cancer who are at high risk for death from 
    prostate cancer.<br><em>J Urol, </em><b>2006</b><i>, 176</i>, S11-S15.</p>
    
    

<p>Guidelines on Prostate Cancer of the European Association of Urology (EAU), <a href="https://uroweb.org/guidelines/prostate-cancer/">https://uroweb.org/guidelines/prostate-cancer/</a>.</p>


<p><a NAME="Harisinghani2003">
    Harisinghani u.a. 2003 H<SMALL>ARISINGHANI</SMALL>, M.&nbsp;G.&nbsp;;
      B<SMALL>ARENTSZ</SMALL>, J.&nbsp;; H<SMALL>AHN</SMALL>, P.&nbsp;F.&nbsp;; D<SMALL>ESERNO</SMALL>, W.&nbsp;M.&nbsp;;
      T<SMALL>ABATABAEI</SMALL>, S.&nbsp;; K<SMALL>AA</SMALL>, C.&nbsp;H. van&nbsp;de&nbsp;; R<SMALL>OSETTE</SMALL>, J.
      de&nbsp;la&nbsp;; W<SMALL>EISSLEDER</SMALL>, R.:
    </a>
     Noninvasive detection of clinically occult lymph-node metastases in
      prostate cancer.
    <br> In: <I>N Engl J Med</I>
    <br> 348 (2003), Nr.&nbsp;25, S.&nbsp;2491&ndash;9</p>

<p>
Javed, S.; Chadwick, E.; Edwards, A. A.; Beveridge, S.; 
    Laing, R.; Bott, S.; Eden, C. &amp; Langley, S.
    Does prostate 
    HistoScanning&#8482; play a role in detecting prostate cancer in routine 
    clinical practice? Results from three independent studies.<br><em>BJU Int, </em><b>2014</b><i>, 
    114</i>, 541-548</p>

    
<p><a NAME="Kattan1998">
    Kattan u.a. 1998 K<SMALL>ATTAN</SMALL>, M.&nbsp;W.&nbsp;; E<SMALL>ASTHAM</SMALL>,
      J.&nbsp;A.&nbsp;; S<SMALL>TAPLETON</SMALL>, A.&nbsp;M.&nbsp;; W<SMALL>HEELER</SMALL>, T.&nbsp;M.&nbsp;;
      S<SMALL>CARDINO</SMALL>, P.&nbsp;T.:
    </a>
     A preoperative nomogram for disease recurrence following radical
      prostatectomy for prostate cancer.
    <br> In: <I>J Natl Cancer Inst</I>
    <br> 90 (1998), Nr.&nbsp;10, S.&nbsp;766&ndash;71</p>

<p>
<a NAME="Kattan2001b">
Kattan u.a. 2001 K<SMALL>ATTAN</SMALL>, M.&nbsp;W.&nbsp;; P<SMALL>OTTERS</SMALL>, L.&nbsp;;
  B<SMALL>LASKO</SMALL>, J.&nbsp;C.&nbsp;; B<SMALL>EYER</SMALL>, D.&nbsp;C.&nbsp;; F<SMALL>EARN</SMALL>, P.&nbsp;;
  C<SMALL>AVANAGH</SMALL>, W.&nbsp;; L<SMALL>EIBEL</SMALL>, S.&nbsp;; S<SMALL>CARDINO</SMALL>, P.&nbsp;T.:
</a>
 Pretreatment nomogram for predicting freedom from recurrence after
  permanent prostate brachytherapy in prostate cancer.
<br> In: <I>Urology</I>
    <br> 58 (2001), Nr.&nbsp;3, S.&nbsp;393&ndash;9</p>

<p>
<a NAME="Kattan2003b">
Kattan u.a. 2003 K<SMALL>ATTAN</SMALL>, M.&nbsp;W.&nbsp;; Z<SMALL>ELEFSKY</SMALL>,
  M.&nbsp;J.&nbsp;; K<SMALL>UPELIAN</SMALL>, P.&nbsp;A.&nbsp;; C<SMALL>HO</SMALL>, D.&nbsp;; S<SMALL>CARDINO</SMALL>,
  P.&nbsp;T.&nbsp;; F<SMALL>UKS</SMALL>, Z.&nbsp;; L<SMALL>EIBEL</SMALL>, S.&nbsp;A.:
</a>
 Pretreatment nomogram that predicts 5-year probability of metastasis
  following three-dimensional conformal radiation therapy for localized
  prostate cancer.
<br> In: <I>J Clin Oncol</I>
    <br> 21 (2003), Nr.&nbsp;24, S.&nbsp;4568&ndash;71</p>


<p>
    Perdon&#224;, S.; Cavadas, V.; Lorenzo, G. D.; Damiano, R.; 
        Chiappetta, G.; Prete, P. D.; Franco, R.; Azzarito, G.; Scala, S.; Arra, 
        C.; Sio, M. D. &amp; Autorino, R.
        Prostate Cancer Detection in the 
        &quot;Grey Area&quot; of Prostate-Specific Antigen Below 10 ng/ml: Head-to-Head 
        Comparison of the Updated PCPT Calculator and Chun's Nomogram, Two Risk 
        Estimators Incorporating Prostate Cancer Antigen 3.<br><em>Eur Urol, </em><b>2010</b>
</p>
    

<p>Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe,
    AWMF): 
    Interdisziplin&auml;re Leitlinie der Qualit&auml;t S3 zur Fr&uuml;herkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 3.1, 2014 AWMF Registernummer: 034/022OL, <a href="https://www.awmf.org//leitlinien/detail/ll/043-022OL.html">https://www.awmf.org//leitlinien/detail/ll/043-022OL.html</a> (Zugriff am: 07.02.2016)</p>
    

<p>Wein, A. J.; Kavoussi, L. R.; Partin, A. P. &amp; Peters, C. A.
    Campbell-Walsh Urology<br><em>. Elsevier, </em><b>2015</b>. ISBN 978-1455775675.</p>

<p><a NAME="Sanz2004">
    Sanz u.a. 2004 S<SMALL>ANZ</SMALL>, G.&nbsp;; R<SMALL>IOJA</SMALL>, J.&nbsp;;
      Z<SMALL>UDAIRE</SMALL>, J.&nbsp;J.&nbsp;; B<SMALL>ERIAN</SMALL>, J.&nbsp;M.&nbsp;; R<SMALL>ICHTER</SMALL>, J.&nbsp;A.:
    </a>
     PET and prostate cancer.
    <br> In: <I>World J Urol</I>
    <br> 22 (2004), Nr.&nbsp;5, S.&nbsp;351&ndash;2</p>

<p>Schiffmann, J.; Tennstedt, P.; Fischer, J.; Tian, Z.; 
        Beyer, B.; Boehm, K.; Sun, M.; Gandaglia, G.; Michl, U.; Graefen, M. &amp; 
        Salomon, G.
        Does HistoScanning&#8482; predict positive results in prostate 
        biopsy? A retrospective analysis of 1,188 sextants of the prostate.<br><em>World 
        J Urol, </em><b>2014</b><i>, 32</i>, 925-930.</p>
        
 <p>       <a NAME="Smaletz2002">
            Smaletz u.a. 2002 S<SMALL>MALETZ</SMALL>, O.&nbsp;; S<SMALL>CHER</SMALL>, H.&nbsp;I.&nbsp;;
              S<SMALL>MALL</SMALL>, E.&nbsp;J.&nbsp;; V<SMALL>ERBEL</SMALL>, D.&nbsp;A.&nbsp;; M<SMALL>C</SMALL>M<SMALL>ILLAN</SMALL>, A.&nbsp;;
              R<SMALL>EGAN</SMALL>, K.&nbsp;; K<SMALL>ELLY</SMALL>, W.&nbsp;K.&nbsp;; K<SMALL>ATTAN</SMALL>, M.&nbsp;W.:
            </a>
             Nomogram for overall survival of patients with progressive metastatic
              prostate cancer after castration.
            <br> In: <I>J Clin Oncol</I>
            <br> 20 (2002), Nr.&nbsp;19, S.&nbsp;3972&ndash;82</p>

<p>
<a NAME="Wawroschek2003">
Wawroschek u.a. 2003 W<SMALL>AWROSCHEK</SMALL>, Friedhelm&nbsp;;
  W<SMALL>AGNER</SMALL>, Theodor&nbsp;; H<SMALL>AMM</SMALL>, Michael&nbsp;; W<SMALL>ECKERMANN</SMALL>,
  Dorothea&nbsp;; V<SMALL>OGT</SMALL>, Harry&nbsp;; M&auml;<SMALL>RKL</SMALL>, Bruno&nbsp;; G<SMALL>ORDIJN</SMALL>,
  Ronald&nbsp;; H<SMALL>ARZMANN</SMALL>, Rolf:
</a>
 The influence of serial sections, immunohistochemistry, and extension
  of pelvic lymph node dissection on the lymph node status in clinically
  localized prostate cancer.
<br> In: <I>Eur Urol</I>
    <br> 43 (2003), Feb, Nr.&nbsp;2, S.&nbsp;132&ndash;6; discussion 137</p>


<br>
<br>
<p><img src="https://images0.urology-textbook.com/deutsch.gif">&nbsp; Deutsche Version: <a href="https://www.urologielehrbuch.de/prostatakarzinom.html">Prostatakarzinom</a></p>    

</article>
</main>
<footer class="grid">
    <ul id="footer-nav">
    		<li>Copyright by Dr. med. Dirk Manski </li>
		<li><a href="https://www.urology-textbook.com/privacy-policy.html">Privacy policy</a></li>
		<li><a href="https://www.urology-textbook.com/disclaimer.html">Disclaimer</a></li>
	</ul>
	<a class="steady-login-button" data-size="medium" data-language="en" style="display: none;"></a>
</footer>
</body>
</html>
